Rating Rationale
June 25, 2020 | Mumbai
Amoli Organics Private Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.234.82 Crore
Long Term Rating CRISIL BBB+/Positive (Reaffirmed)
Short Term Rating CRISIL A2 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its ratings on the bank facilities of Amoli Organics Private Limited (AOPL) at 'CRISIL BBB+/Positive/CRISIL A2'.
 
The measures taken by various central and state governments towards containment of COVID-19 are not expected to impact the business risk profile of AOPL, as the company's operations are classified as essential with presence in export as well as domestic market and plant is operational.
 
The ratings continue to reflect promoters' extensive industry experience and their established customer relationships. Ratings also factor in the company's healthy financial risk profile marked by comfortable capital structure and debt protection metrics. These strengths are partially offset by its working capital-intensive nature of operations, and susceptibility of operating performance to product concentration risk, raw material price fluctuations and regulatory risks.

Key Rating Drivers & Detailed Description
Strengths: 
* Promoters' extensive industry experience and established customer relationships: AOPL has been active in the Active Pharmaceutical Ingredients (API) manufacturing segment since 1991, and its promoters have over 3 decades of relevant industry experience. On the back of constant upgrades in production facilities and R&D, the company has obtained approvals from various regulatory authorities and has established healthy relations with customers.
 
* Healthy financial risk profile: A moderate total outside liabilities to adjusted networth (TOLANW) of less than 1.5 times on a networth base of estimated at over Rs 180 crore as on March 31, 2020 depicts a comfortable capital structure. Interest coverage ratio estimated at above 6.7 times fiscal 2020, confirms adequacy. The financial risk profile is expected to remain healthy with steady accretion to reserves.
 
Weaknesses:
* Working capital intensive operations: AOPL's operations are working capital intensive as reflected in gross current assets (GCAs) in the range of 200-220 days for last 3 years ending March 2020 primarily driven by receivables of around 103-123 days. Incremental working capital requirements arising from sharp growth, spontaneous operational requirements or capex to remain key rating factor.
 
* Susceptibility of operating performance to product concentration risk, raw material price fluctuations and regulatory risk: Revenue could be impacted as, company derives around 30-35% of revenue from the single product, while operating profitability will remain susceptible to any sharp changes in raw material prices or competition from peers over the medium term. Further, being in pharmaceutical industry, the operations of the company remains susceptible to regulatory changes both in domestic and export market.
Liquidity Adequate

AOPL has moderate liquidity driven by expected cash accruals of more than Rs. 60 crore per annum in fiscal 2021 and 2022 and cash and cash equivalents of Rs.3.9 crore as on March 31, 2019. The company's fund based limits have remained utilized to the tune of 86.54% on an average over the 12 months ended March 2020. The company has long term repayment obligation of Rs 10-14 crore and capex is expected to be around Rs. 25-40 crore each over fiscal 2021 and 2022; partly funded by debt. CRISIL believes the company has sufficient accruals and cash and cash equivalents to part finance its capex requirements and incremental working capital needs.

Outlook: Positive

CRISIL believes AOPL will continue to benefit from extensive experience of promoters and established relationships with reputed pharmaceutical companies over the medium term.

Rating Sensitivity factors
Upward factor
* Healthy cash accruals driven by significant improvement in revenue and sustenance of operating margin above 17%
* Sustaining the financial risk profile, driven by low working capital cycle
 
Downward factor
* Any debt-funded capital expenditure or a stretch in the working capital cycle, leading to weakening of the financial risk profile
* Decline in revenue by over 20% and profitability by over 200 basis points, resulting in a reduction in cash accrual
About the Company

AOPL was incorporated by Mr Manish Doshi and Mr Umed Doshi in 1991. It manufactures bulk drugs/active pharmaceutical ingredients, and caters primarily to the anti-inflammatory, anti-fungal, and anti-depressant segments. Its manufacturing facilities are at Vapi and Vadodara in Gujarat.

Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs crore 465.47 405.44
Profit After Tax (PAT) Rs crore 32.41 27.20
PAT Margin % 7 6.7
Adjusted debt/adjusted networth Times 0.86 0.90
Interest coverage Times 6.87 6.28

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon rate (%) Maturity date Issue size
(Rs crore)
Complexity levels Rating assigned
with outlook
NA Bank Guarantee NA NA NA 2.5 NA CRISIL A2
NA Cash Credit NA NA NA 92 NA CRISIL BBB+/Positive
NA External Commercial Borrowings NA NA Jun-2024 20 NA CRISIL BBB+/Positive
NA FCNR (B) Long Term Loan NA NA Mar-2025 30.43 NA CRISIL BBB+/Positive
NA Letter of Credit NA NA NA 32 NA CRISIL A2
NA Proposed Cash Credit Limit NA NA NA 25 NA CRISIL BBB+/Positive
NA Proposed Letter of Credit NA NA NA 10 NA CRISIL A2
NA Proposed Long Term Bank Loan Facility NA NA NA 13.45 NA CRISIL BBB+/Positive
NA Rupee Term Loan NA NA Jun-2024 4.44 NA CRISIL BBB+/Positive
NA Standby Line of Credit NA NA NA 5 NA CRISIL BBB+/Positive
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  190.32  CRISIL BBB+/Positive      13-12-19  CRISIL BBB+/Positive  23-08-18  CRISIL BBB+/Stable/ CRISIL A2  24-04-17  CRISIL BBB/Stable/ CRISIL A3+  CRISIL BBB/Stable/ CRISIL A3+ 
            06-12-19  CRISIL BBB+/Positive/ CRISIL A2  16-08-18  CRISIL BBB+/Stable/ CRISIL A2       
            30-03-19  CRISIL BBB+/Stable/ CRISIL A2           
            07-03-19  CRISIL BBB+/Stable/ CRISIL A2           
Non Fund-based Bank Facilities  LT/ST  44.50  CRISIL A2      13-12-19  CRISIL A2  23-08-18  CRISIL A2  24-04-17  CRISIL A3+  CRISIL A3+ 
            06-12-19  CRISIL A2  16-08-18  CRISIL A2       
            30-03-19  CRISIL A2           
            07-03-19  CRISIL A2           
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 2.5 CRISIL A2 Bank Guarantee 2.5 CRISIL A2
Cash Credit 92 CRISIL BBB+/Positive Cash Credit 92 CRISIL BBB+/Positive
External Commercial Borrowings 20 CRISIL BBB+/Positive External Commercial Borrowings 20 CRISIL BBB+/Positive
FCNR (B) Long Term Loan 30.43 CRISIL BBB+/Positive FCNR (B) Long Term Loan 10.43 CRISIL BBB+/Positive
Letter of Credit 32 CRISIL A2 Letter of Credit 32 CRISIL A2
Proposed Cash Credit Limit 25 CRISIL BBB+/Positive Proposed Cash Credit Limit 25 CRISIL BBB+/Positive
Proposed Letter of Credit 10 CRISIL A2 Proposed Letter of Credit 10 CRISIL A2
Proposed Long Term Bank Loan Facility 13.45 CRISIL BBB+/Positive Proposed Long Term Bank Loan Facility 13.45 CRISIL BBB+/Positive
Rupee Term Loan 4.44 CRISIL BBB+/Positive Proposed Term Loan 20 CRISIL BBB+/Positive
Standby Line of Credit 5 CRISIL BBB+/Positive Rupee Term Loan 4.44 CRISIL BBB+/Positive
-- 0 -- Standby Line of Credit 5 CRISIL BBB+/Positive
Total 234.82 -- Total 234.82 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Rushabh Borkar
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8302
Rushabh.Borkar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL